Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate

EU orphan designation number: EU/3/08/572   
Active ingredient: (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate
Indication: Treatment of chronic idiopathic myelofibrosis
Sponsor: Novartis Europharm Limited
Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Jakavi on 23/08/2012 with the number EU/1/12/773

   Public summary of scientific opinion     EPAR

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
11/11/2008 Centralised Orphan - Designation EMEA/OD/039/08 (2008)6865 of 07/11/2008
01/12/2009 Other procedure
30/09/2010 Centralised Orphan - Transfer of orphan designation EMEA/OD/039/08/T/01 (2010)6807 of 28/09/2010